Siliciano R F, Bollinger R C, Callahan K M, Hammond S A, Liu A Y, Miskovsky E P, Rowell J F, Stanhope P E
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
AIDS Res Hum Retroviruses. 1992 Aug;8(8):1349-52. doi: 10.1089/aid.1992.8.1349.
Both CD4+ and CD8+ CTL responses specific for the HIV-1 envelope proteins can be elicited in seronegative humans by candidate AIDS vaccines. The phenotype of the responding CTL depends upon the nature of the vaccine, with CD8+ CTL being found exclusively in recipients of live virus vaccines. Both types of CTL are active against HIV-1-infected cells in vitro. However, the potential efficacy of vaccine-induced CTL in preventing infection in vaccinated individuals exposed to HIV-1 is unknown and is likely to be dependent upon complex factors including lytic activity against divergent strains, cytokines produced, and the lysis of noninfected CD4+ T cells.
候选艾滋病疫苗可在血清学阴性的人体内引发针对HIV-1包膜蛋白的CD4+和CD8+细胞毒性T淋巴细胞（CTL）反应。反应性CTL的表型取决于疫苗的性质，CD8+ CTL仅在活病毒疫苗接种者中发现。两种类型的CTL在体外均对HIV-1感染的细胞具有活性。然而，疫苗诱导的CTL在预防暴露于HIV-1的接种个体感染方面的潜在功效尚不清楚，并且可能取决于多种复杂因素，包括对不同毒株的裂解活性、产生的细胞因子以及未感染的CD4+ T细胞的裂解。
